| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802356401016 | 235640101 | MABTHERA C/S.SOL.IN 100MG/10ML VIAL BTx2VIALSx10ML | 405.35 | 411.43 | 475.37 |
| 05/2018 | 2802356402013 | 235640201 | MABTHERA CS.INJ.SOL 500MG/50ML BTx1VIALx50ML | 1018.76 | 1034.04 | 1150.88 |
| 05/2018 | 2802356403010 | 235640301 | MABTHERA INJ.SOL 1400MG/11.7ML BTxVIALx15ml | 1450.52 | 1472.28 | 1626.94 |
For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis.
0.8 hours (mammalian reticulocytes, in vitro)
* 3.1 L
* 0.34 L/day [RA patients]